-
Government RegulationHims? Hers? It’s Novo Nordisk’s Semaglutide Market Now
Between Feb. 19-26, shares for the telehealth company Hims & Hers Health, Inc. plummeted. The reason for the sudden drop in its stock price? An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage.
-
Artificial IntelligenceWhen Clinical Trials Meet Patents: Finding Balance in Law
-
Food SafetyDecoding Front-of-Package Food Labels: Are They Really Telling Us What’s Healthy?
-
Artificial IntelligenceMind over Machine: Navigating the Legal and Ethical Frontier of Neurotech
Latest
Symposia
Critical conversations around issues in health law policy, biotechnology, and bioethics.
About Bill of Health
Bill of Health, the blog of the Petrie-Flom Center at Harvard Law School, is a leading forum for health law policy and bioethical perspectives from domestic and international thought leaders.
Posts from Bill of Health are regularly cited in prominent, diverse media outlets ranging from the New York Times to the Los Angeles Times to USA Today to the New York Review of Books.